Vistagen Therapeutics Inc VTGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VTGN is a good fit for your portfolio.
News
-
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
-
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
-
Vistagen to Present at Stifel 2024 Virtual CNS Days
-
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
-
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
-
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
Trading Information
- Previous Close Price
- $4.83
- Day Range
- $4.65–4.86
- 52-Week Range
- $1.62–24.71
- Bid/Ask
- $4.65 / $4.87
- Market Cap
- $127.56 Mil
- Volume/Avg
- 147,555 / 264,197
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 62.63
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
- Website
- https://www.vistagen.com
Valuation
|
Metric
|
VTGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.06 |
Price/Sales | 62.63 |
Price/Cash Flow | — |
Price/Earnings
VTGN
Financial Strength
|
Metric
|
VTGN
|
|---|---|
Quick Ratio | 30.39 |
Current Ratio | 30.76 |
Interest Coverage | — |
Quick Ratio
VTGN
Profitability
|
Metric
|
VTGN
|
|---|---|
Return on Assets (Normalized) | −63.33% |
Return on Equity (Normalized) | −76.26% |
Return on Invested Capital (Normalized) | −74.73% |
Return on Assets
VTGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tqdjrjbtp | Rfjvt | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ycmgxnh | Hxqszk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cbsdzzydm | Kbhlf | $99.5 Bil | |
MRNA
| Moderna Inc | Krvrtysx | Mgcmc | $38.8 Bil | |
ARGX
| argenx SE ADR | Vpfhkftn | Gxqtg | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Vqtjxysh | Mljz | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gmxvwcb | Lmxnr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Psdvqgw | Fbvhm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wqlnnvvkx | Jhyndcf | $12.5 Bil | |
INCY
| Incyte Corp | Gbwyycrk | Zghqsqx | $11.6 Bil |